People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Pharmaceuticals, Biotechnology, Hospitals and Physicians
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CerSci Therapeutics Inc. | — | Pharmaceuticals | Series A | $12.0M | $371.7M | 2019 |
| Dialectic Therapeutics, Inc. | — | Biotechnology | Series A | $8.8M | $184.0M | 2018 |
| Cessation Therapeutics, Inc. | — | Biotechnology | Series A | $6.8M | $5.9M | 2022 |
| Forest Park Medical Center, LLC | — | Hospitals and Physicians | Seed | $1.3M | $2.5M | — |
David Genecov at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Genecov on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wade Barker | 1 | 6 |
| Richard Toussaint | 1 | 6 |
| John D. Harkey, Jr. | 1 | 5 |
| Scott Wilson | 1 | 5 |
| Sharon Tetlow | 1 | 4 |
| Jay Shepard | 1 | 3 |
| Daniel Fine | 1 | 3 |
| Tyler Brous | 1 | 3 |
| Perry Molinoff | 1 | 3 |
| John Harkey | 1 | 3 |
| John D. Harkey | 1 | 3 |
| Robert Wyatt | 1 | 2 |
| Brent Duncan | 1 | 2 |
| Eric Rasmussen | 1 | 2 |
| Thomas Hung | 1 | 1 |
| Andrew Barrett | 1 | 1 |
| Mark Pearson | 1 | 1 |
| Daohong Zhou | 1 | 1 |
| Joshua D. Sills | 1 | 1 |
| Robert Hromas | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.